Product
Temozolomide + Lorlatinib
1 clinical trial
2 indications
Indication
Lung CancerIndication
Central Nervous System ProgressionClinical trial
A Phase 1 Study of Temozolomide in Combination With Targeted Therapy for NSCLC Patients With CNS Progression on Either Osimertinib or LorlatinibStatus: Completed, Estimated PCD: 2022-04-25